Elicio Therapeutics reports Q4 loss of $7.7 million

Biotech company Elicio Therapeutics announced its fourth quarter financial results.

Mar. 12, 2026 at 10:08pm

Got story updates? Submit your updates here. ›

Elicio Therapeutics, Inc. (ELTX), a Boston-based biotech company, reported a loss of $7.7 million in its fourth quarter, according to an announcement from the company.

Why it matters

Elicio Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. Its quarterly financial results provide insight into the company's performance and progress in advancing its pipeline of experimental treatments.

The details

In its Q4 2026 financial report, Elicio Therapeutics stated that it incurred a net loss of $7.7 million. The company did not provide additional details on the specific factors contributing to the quarterly loss.

  • Elicio Therapeutics reported its Q4 2026 financial results on March 12, 2026.

The players

Elicio Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies.

Got photos? Submit your photos here. ›

The takeaway

Elicio Therapeutics' Q4 2026 financial results provide a glimpse into the company's financial performance as it continues to advance its pipeline of experimental cancer treatments. Investors and analysts will likely closely monitor the company's future financial reports to assess its progress and prospects.